Manufactures and sells Symvess, a bioengineered blood vessel, and develops other engineered tissues for hospitals, trauma centers and outpatient surgical settings.
10-K for FY2025, filed Mar 27, 2026
10-K for FY2025, filed Mar 27, 2026
FY2025 revenue by product or service ↗$2M
10-K for FY2025, filed Mar 27, 2026
$2M ↗| Segment | Share | Revenue |
|---|---|---|
|
Product
|
68% |
Product, FY2025
$1.4M Sources
|
|
Contract Revenue
|
32% |
Contract Revenue, FY2025
$649K Sources
|
Humacyte reaches U.S. trauma centers through its own sales and marketing team and is pursuing partners with established distribution channels for specialized markets.
10-K for FY2025, filed Mar 27, 2026
No. It lost $40.8M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$15.5MView ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
Open tableView ↗
8-K, filed Nov 10, 2026
Symvess commercial growth accelerated entering the fourth quarter, with October 2026 sales reaching $0.8 million and Q4 2026 sales expected…View ↗
8-K, filed Jul 31, 2026
On July 31, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”)…View ↗
8-K, filed Apr 24, 2026
On April 21, 2026, Humacyte, Inc. (the “Company”) entered into the Third Amendment to Distribution Agreement (the “Amendment”) with…View ↗
Growing. Revenue grew 61% in 4 years, from $1.3M in FY2021 to $2M in FY2025, about 13% a year.
Commercial launch
The older report described the vessels as investigational, while the latest report says Symvess received U.S. Food and Drug Administration approval and commercial sales began in the United States.
10-K for FY2022, filed Mar 24, 2023 10-K for FY2025, filed Mar 27, 2026
Competes with Bard Peripheral Vascular, W.L. Gore & Associates, Terumo Medical Systems, and Atrium
10-K for FY2025, filed Mar 27, 2026There are several conventional synthetic grafts made of ePTFE or Dacron presently on the market from companies such as Bard Peripheral…View ↗
Loading...